14-day Premium Trial Subscription Sign Up For FreeGet Free

No Pain, No Gain.Week 21 On Stock Market Click to watch.

Brainstorm Cell Therapeutics Inc. Stock Forecast

NASDAQ:BCLI BUY SELL

$2.95 (2.08%)

Volume: 32.716k

Closed: May 23, 2022

Hollow Logo Score: -1.959

Brainstorm Cell Therapeutics Inc. Stock Forecast

BUY SELL NASDAQ:BCLI
$2.95 (2.08%)

Volume: 32.716k

Closed: May 23, 2022

Score Hollow Logo -1.959

Brainstorm Cell Therapeutics Inc. Stock Forecast NASDAQ:BCLI

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2021-02-05 - Maxim Group - Upgrades Hold Buy

BCLI Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -8.56% during the next 3 months and, with a 90% probability hold a price between $2.44 and $3.14 at the end of this 3-month period.

Data

Date Bottom Mid Top
2022-05-25 $2.66 $3.04 $3.42
2022-05-26 $2.66 $3.04 $3.42
2022-05-27 $2.65 $3.03 $3.41
2022-05-31 $2.65 $3.03 $3.41
2022-06-01 $2.64 $3.02 $3.40
2022-06-02 $2.64 $3.02 $3.40
2022-06-03 $2.63 $3.01 $3.39
2022-06-06 $2.63 $3.01 $3.39
2022-06-07 $2.62 $3.00 $3.38
2022-06-08 $2.62 $3.00 $3.38
2022-06-09 $2.61 $2.99 $3.37
2022-06-10 $2.60 $2.99 $3.37
2022-06-13 $2.60 $2.98 $3.36
2022-06-14 $2.59 $2.98 $3.36
2022-06-15 $2.59 $2.97 $3.35
2022-06-16 $2.58 $2.96 $3.35
2022-06-17 $2.58 $2.96 $3.34
2022-06-21 $2.57 $2.95 $3.34
2022-06-22 $2.57 $2.95 $3.33
2022-06-23 $2.56 $2.94 $3.32
2022-06-24 $2.56 $2.94 $3.32
2022-06-27 $2.55 $2.93 $3.31
2022-06-28 $2.55 $2.93 $3.31
2022-06-29 $2.54 $2.92 $3.30
2022-06-30 $2.54 $2.92 $3.30
2022-07-01 $2.53 $2.91 $3.29
2022-07-05 $2.53 $2.91 $3.29
2022-07-06 $2.52 $2.90 $3.28
2022-07-07 $2.52 $2.90 $3.28
2022-07-08 $2.51 $2.89 $3.27

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cell... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!
.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT